AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2111982 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression
Number of subjects: 79
Study 296397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% tiodonium chloride mouthrinse
Number of subjects: 55
Study 296397 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 55
Study 31728673 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg/day prednisone
Number of subjects: 30
Study 31728673 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg/day prednisone
Number of subjects: 30
Study 31728673 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day prednisone
Number of subjects: 30
Study 31728673 — intervention group
Group type: COMPARATOR
Intervention: Cumulative prednisone dose for 2 mg/kg/day
Number of subjects: 30
Study 31728673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative prednisone dose for 1.5 mg/kg/day
Number of subjects: 30
Study 31728673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative prednisone dose for 1 mg/kg/day
Number of subjects: 30
Study 31099599 — intervention group
Group type: EXPERIMENTAL
Intervention: MacConkey agar medium supplemented with 8 mg/L of ceftiofur (MC-CEF)
Number of subjects: 773
Study 31099599 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected E. coli (RSEC)
Number of subjects: 773
Study 25526873 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping with cord stripping (test arm)
Number of subjects: 67
Study 25526873 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping (control arm)
Number of subjects: 67
Study 23415615 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel lance treated with sucrose and non‐nutritive sucking
Number of subjects: 131
Study 23415615 — intervention group
Group type: COMPARATOR
Intervention: Heel lance treated with placebo and non‐nutritive sucking
Number of subjects: 131
Study 23415615 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131
Study 20876366 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 40
Study 20876366 — intervention group
Group type: COMPARATOR
Intervention: Non-diuretic antihypertensive treatment (Control)
Number of subjects: 40
Study 18647431 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based food garden intervention
Number of subjects: 252
Study 17202205 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 20
Study 17202205 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy associated with systemic steroids (SS + PDT)
Number of subjects: 20
Study 14976306 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 11323577 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral hepatic duct drainage (group A)
Number of subjects: 157
Study 11323577 — intervention group
Group type: COMPARATOR
Intervention: Bilateral hepatic duct drainage (group B)
Number of subjects: 157
Study 11323577 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 157
Study 9460279 — intervention group
Group type: EXPERIMENTAL
Intervention: One mammary artery
Number of subjects: 216
Study 9460279 — intervention group
Group type: EXPERIMENTAL
Intervention: Two mammary arteries
Number of subjects: 216
Study 8194502 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (two types)
Number of subjects: 119
Study 8194502 — intervention group
Group type: COMPARATOR
Intervention: Caffeinated coffee
Number of subjects: 119
Study 2886822 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose maintained at 3.2 mmol/l
Number of subjects: 25
Study 2886822 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose maintained at 2.5 mmol/l for 30 min
Number of subjects: 25
Study 2886822 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose raised to 4.5 mmol/l
Number of subjects: 25
Study 29852078 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise test (4-min stages)
Number of subjects: 15
Study 29852078 — intervention group
Group type: EXPERIMENTAL
Intervention: Short continuous exercise sessions (SCEequal)
Number of subjects: 15
Study 29852078 — intervention group
Group type: COMPARATOR
Intervention: Graded exercise test
Number of subjects: 15
Study 28607897 — intervention group
Group type: EXPERIMENTAL
Intervention: Two layers pharyngeal repair
Number of subjects: 21
Study 28607897 — intervention group
Group type: COMPARATOR
Intervention: Three layers pharyngeal repair
Number of subjects: 21
Study 26037024 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Esophagectomy (MIE)
Number of subjects: 0
Study 26037024 — intervention group
Group type: COMPARATOR
Intervention: Open Esophagectomy (OE)
Number of subjects: 0
Study 23009573 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music during procedure (Group II)
Number of subjects: 70
Study 23009573 — intervention group
Group type: COMPARATOR
Intervention: No music (Group I)
Number of subjects: 70
Study 20538327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (defined as 25-hydroxyvitamin D level of 30 ng/mL or less)
Number of subjects: 1024
Study 18160303 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1‐8)
Number of subjects: 101
Study 18160303 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (35 mg/m2 days 1‐8‐15)
Number of subjects: 101
Study 18160303 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 101
Study 18160303 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 101
Study 16169319 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (100-200 mg/d)
Number of subjects: 168
Study 16169319 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50-100 mg/d)
Number of subjects: 168
Study 16169319 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone and Losartan
Number of subjects: 168
Study 12896935 — intervention group
Group type: EXPERIMENTAL
Intervention: 24,000 IU oral vitamin A on days 1 and 2 after delivery
Number of subjects: 11619
Study 12896935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11619
Study 10587773 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions for people after suicide attempts
Number of subjects: 10
Study 10587773 — intervention group
Group type: EXPERIMENTAL
Intervention: Principles of care after a suicide attempt
Number of subjects: 10
Study 8671908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 15
Study 8671908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1660550 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (5%, 10%, and 20% of the pressor dose)
Number of subjects: 6
Study 1660550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE inhibitor)
Number of subjects: 6
Study 1660550 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study 6751131 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-oriented insight group therapy
Number of subjects: 3
Study 6751131 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled drinking-oriented behavioral modification group therapy
Number of subjects: 3
Study 6751131 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 31743822 — intervention group
Group type: EXPERIMENTAL
Intervention: Grinding (Gr)
Number of subjects: 5
Study 31743822 — intervention group
Group type: EXPERIMENTAL
Intervention: Grinding + Polishing (Gr + Pol)
Number of subjects: 5
Study 31743822 — intervention group
Group type: EXPERIMENTAL
Intervention: Grinding + Glaze (Gr + Gl)
Number of subjects: 5
Study 31743822 — intervention group
Group type: EXPERIMENTAL
Intervention: Grinding + Polishing + Glaze (Gr + Pol + Gl)
Number of subjects: 5
Study 31743822 — intervention group
Group type: COMPARATOR
Intervention: Control (Ctrl) - as-sintered
Number of subjects: 5
Study 31652034 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath MAC X-Blade videolaryngoscope
Number of subjects: 80
Study 28598681 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate and adalimumab (ADA)
Number of subjects: 155
Study 28598681 — intervention group
Group type: COMPARATOR
Intervention: methotrexate and placebo (PLA)
Number of subjects: 155
Study 26218411 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC, 3 pretreatment education sessions)
Number of subjects: 230
Study 26218411 — intervention group
Group type: EXPERIMENTAL
Intervention: SoC and automated text reminders if dosing >30 minutes late
Number of subjects: 230
Study 26218411 — intervention group
Group type: COMPARATOR
Intervention: Control group (SoC)
Number of subjects: 230
Study 26218411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (SoC + text reminders)
Number of subjects: 230
Study 23539462 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sutureless manual small-incision cataract surgery (M-MSICS)
Number of subjects: 21
Study 21346207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low spatial frequency (SF) grating
Number of subjects: 0
Study 21346207 — intervention group
Group type: EXPERIMENTAL
Intervention: High spatial frequency (SF) grating
Number of subjects: 0
Study 21346207 — intervention group
Group type: EXPERIMENTAL
Intervention: Filter-rectify-normalize-filter model (extended FRF model)
Number of subjects: 0
Study 19496102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 50
Study 19496102 — intervention group
Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy (STPP)
Number of subjects: 50
Study 17535864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.033 mg/kg s.c.
Number of subjects: 20
Study 17535864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.083 mg/kg s.c.
Number of subjects: 20
Study 17535864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.033 mg/kg i.m.
Number of subjects: 20
Study 17535864 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH administration
Number of subjects: 20
Study 17535864 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 20
Study 17535864 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-3 concentrations
Number of subjects: 20
Study 15510886 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with phentanyl (Group I)
Number of subjects: 60
Study 15510886 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine appropriate for the need of the patient (Group II)
Number of subjects: 60
Study 15510886 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 15510886 — intervention group
Group type: COMPARATOR
Intervention: Both methods of analgesia
Number of subjects: 60
Study 11564024 — intervention group
Group type: EXPERIMENTAL
Intervention: Easicath
Number of subjects: 61
Study 11564024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofric
Number of subjects: 61
Study 11564024 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacath
Number of subjects: 61
Study 11564024 — intervention group
Group type: EXPERIMENTAL
Intervention: Silky
Number of subjects: 61
Study 9624225 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake (80 mmol/d)
Number of subjects: 29
Study 9624225 — intervention group
Group type: COMPARATOR
Intervention: High sodium intake (180 mmol/d)
Number of subjects: 29
Study 9624225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (80 and 180 mmol/d)
Number of subjects: 29
Study 7827853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low-friction self-catheterization (ILSC) for more than 12 months
Number of subjects: 101
Study 7827853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low-friction self-catheterization (ILSC) for 6 months
Number of subjects: 101
Study 3371886 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 154
Study 3371886 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 154
Study 31769337 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily functional electrostimulation group (DFEG; n = 15)
Number of subjects: 48
Study 31769337 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily functional electrostimulation group (TFEG; n = 17)
Number of subjects: 48
Study 31769337 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG; n = 16)
Number of subjects: 48
Study 29886113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional verapamil (2.5 mg/mL)
Number of subjects: 50
Study 29886113 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (40 mg/mL)
Number of subjects: 50
Study 28640988 — intervention group
Group type: EXPERIMENTAL
Intervention: ORAL paliperidone
Number of subjects: 449
Study 28640988 — intervention group
Group type: EXPERIMENTAL
Intervention: PP1M
Number of subjects: 449
Study 28640988 — intervention group
Group type: EXPERIMENTAL
Intervention: PP3M
Number of subjects: 449
Study 26357940 — intervention group
Group type: EXPERIMENTAL
Intervention: AFN-1252 100 mg
Number of subjects: 0
Study 26357940 — intervention group
Group type: EXPERIMENTAL
Intervention: AFN-1252 200 mg
Number of subjects: 0
Study 26357940 — intervention group
Group type: EXPERIMENTAL
Intervention: AFN-1252 300 mg
Number of subjects: 0
Study 26357940 — intervention group
Group type: EXPERIMENTAL
Intervention: AFN-1252 400 mg
Number of subjects: 0
Study 26357940 — intervention group
Group type: EXPERIMENTAL
Intervention: AFN-1252 200 mg (twice daily)
Number of subjects: 0
Study 26357940 — intervention group
Group type: EXPERIMENTAL
Intervention: AFN-1252 400 mg (twice daily)
Number of subjects: 0
Study 26357940 — intervention group
Group type: EXPERIMENTAL
Intervention: AFN-1252 600 mg (total daily dose)
Number of subjects: 0
Study 26357940 — intervention group
Group type: EXPERIMENTAL
Intervention: AFN-1252 800 mg (total daily dose)
Number of subjects: 0
Study 26357940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23159479 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 IU of intranasal oxytocin
Number of subjects: 48
Study 23159479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22004305 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle School Success intervention (MSS)
Number of subjects: 100
Study 22004305 — intervention group
Group type: COMPARATOR
Intervention: Regular foster care control
Number of subjects: 100
Study 18507895 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 447
Study 18507895 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 447
Study 18507895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study 16552801 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR oral administration at the dose of 800‐1200 mg/d for 3 ‐ 5 d
Number of subjects: 60
Study 16552801 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg 5‐FU + 200 mg/d CF by venous drip for 3 ‐ 5 d
Number of subjects: 60
Study 16552801 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 14586743 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (0.5 mg/kg per day of prednisolone)
Number of subjects: 15
Study 14586743 — intervention group
Group type: COMPARATOR
Intervention: Warfarin monotherapy
Number of subjects: 15
Study 10756223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (as-needed usage)
Number of subjects: 52
Study 10756223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 9161190 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealant (Concise White Sealant)
Number of subjects: 53
Study 9161190 — intervention group
Group type: COMPARATOR
Intervention: Light-cured resin-reinforced glass-ionomer cement (Vitrebond)
Number of subjects: 53
Study 1563463 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride subcutaneous infusion
Number of subjects: 8
Study 1563463 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH test (200 micrograms i.v.)
Number of subjects: 8
Study 3909544 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir ophthalmic ointment
Number of subjects: 29
Study 3909544 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir
Number of subjects: 29
Study 3909544 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Acyclovir ointment and Oral acyclovir)
Number of subjects: 29
Study 30466338 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-based safe-transport program (Behind the Wheel)
Number of subjects: 190
Study 30284023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril monotherapy
Number of subjects: 63
Study 30284023 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril and losartan combination therapy
Number of subjects: 63
Study 30284023 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 63
Study 27894058 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure via home-based telehealth (PE-HBT)
Number of subjects: 132
Study 27894058 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Exposure via in-person (PE-IP)
Number of subjects: 132
Study 24571062 — intervention group
Group type: EXPERIMENTAL
Intervention: gabapentin/ketamine/lornoxicam/ropivacaine
Number of subjects: 148
Study 24571062 — intervention group
Group type: EXPERIMENTAL
Intervention: gabapentin/placebo/placebo/placebo
Number of subjects: 148
Study 24571062 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo/placebo/lornoxicam/placebo
Number of subjects: 148
Study 24571062 — intervention group
Group type: COMPARATOR
Intervention: placebo/placebo/placebo/placebo
Number of subjects: 148
Study 23188130 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB combined with QYHJ
Number of subjects: 108
Study 23188130 — intervention group
Group type: COMPARATOR
Intervention: ARB
Number of subjects: 108
Study 21194898 — intervention group
Group type: EXPERIMENTAL
Intervention: GR205171 (N=20)
Number of subjects: 39
Study 21194898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=19)
Number of subjects: 39
Study 19416259 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 microg g(‐1) plus betamethasone 0.5 mg g(‐1) (Xamiol) - once daily
Number of subjects: 312
Study 19416259 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol 50 microg mL(‐1) scalp solution - twice daily
Number of subjects: 312
Study 18001533 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg + amlodipine + benazepril
Number of subjects: 151
Study 18001533 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg + amlodipine + benazepril
Number of subjects: 151
Study 18001533 — intervention group
Group type: COMPARATOR
Intervention: Control group (amlodipine + benazepril)
Number of subjects: 151
Study 15346659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Number of subjects: 32
Study 15346659 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone in oil 50 mg
Number of subjects: 32
Study 11799002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency devices
Number of subjects: 22
Study 11799002 — intervention group
Group type: COMPARATOR
Intervention: Monopolar radiofrequency device
Number of subjects: 22
Study 9587047 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoplanta capsule
Number of subjects: 24
Study 9587047 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune Neoral capsule
Number of subjects: 24
Study 7905217 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 35
Study 7905217 — intervention group
Group type: EXPERIMENTAL
Intervention: Log IC90 and CD4+ count
Number of subjects: 35
Study 3152946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium after cisplatin administration
Number of subjects: 28
Study 3152946 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium before and after cisplatin administration
Number of subjects: 28
Study 15692311 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Number of subjects: 40
Study 15692311 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 31797677 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA-IM (Depo-medroxyprogesterone acetate)
Number of subjects: 0
Study 31797677 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 0
Study 31797677 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-intrauterine device (IUD)
Number of subjects: 0
Study 31797677 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contraception or infrequent condom use)
Number of subjects: 0
Study 31758738 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-ERSPC-3/4
Number of subjects: 307
Study 31758738 — intervention group
Group type: EXPERIMENTAL
Intervention: Radtke's RM
Number of subjects: 307
Study 31758738 — intervention group
Group type: EXPERIMENTAL
Intervention: Distler's RM
Number of subjects: 307
Study 27001344 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic response after neoadjuvant CRT
Number of subjects: 106
Study 27001344 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable disease after neoadjuvant CRT
Number of subjects: 106
Study 27001344 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression after neoadjuvant CRT
Number of subjects: 106
Study 27001344 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative change in FDG uptake after 14 days of CRT
Number of subjects: 106
Study 25310825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol intoxication
Number of subjects: 131
Study 25310825 — intervention group
Group type: COMPARATOR
Intervention: Sober (control)
Number of subjects: 131
Study 25310825 — intervention group
Group type: EXPERIMENTAL
Intervention: Low conflict
Number of subjects: 131
Study 23136231 — intervention group
Group type: EXPERIMENTAL
Intervention: DD-MVAC (M 30 mg/m(2), V 3 mg/m(2), A 30 mg/m(2), C 70 mg/m(2) q 2 weeks)
Number of subjects: 130
Study 23136231 — intervention group
Group type: COMPARATOR
Intervention: DD-GC (G 2500 mg/m(2), C 70 mg/m(2) q 2 weeks)
Number of subjects: 130
Study 23136231 — intervention group
Group type: COMPARATOR
Intervention: DD-GC
Number of subjects: 130
Study 23136231 — intervention group
Group type: EXPERIMENTAL
Intervention: DD-MVAC
Number of subjects: 130